This area studies compounds involved in sexual-response signaling — the best known is PT-141 (bremelanotide), which also exists as an FDA-approved medicine (Vyleesi) for a specific condition. Research-chemical versions are not the approved drug.
PT-141 is the research name for bremelanotide, which the FDA approved in 2019 under the brand name Vyleesi. It is a melanocortin receptor agonist approved for one narrow, specific use: premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD) — persistent low sexual desire that causes distress and is not explained by another medical, psychiatric, relationship, or medication cause. That approval is backed by real human clinical trials.
The measured effect in those trials was modest and statistical, not dramatic. The FDA label is also explicit about limits: it is not approved for postmenopausal women, not for men, and not to 'enhance performance.' It carries warnings, including around blood pressure, and is meant to be used under prescription.
The crucial honesty point: a vial of 'PT-141' sold as a research chemical is not the FDA-approved Vyleesi product. It has not gone through that drug's manufacturing controls, purity testing, dosing work, or safety labeling. So while the underlying molecule genuinely has an approved medical version, that does not transfer to research-chemical material bought and used outside of medical care.
Sources: VYLEESI (bremelanotide) FDA prescribing information / label (FDA) · Bremelanotide for Female Hypoactive Sexual Desire Disorder — review (NCBI PMC) · How we source this ›
Each links to a full profile — identity, what it is, regulatory status, storage, and cited sources. Everything is framed for research use only; none of this is a recommendation to take anything.
Kisspeptin-10 is the C-terminal decapeptide of the KiSS-1 / metastin protein (residues 45-54) and the shortest fully active kisspeptin fragment.
Oxytocin is a naturally occurring nonapeptide hormone made in the hypothalamus and released from the posterior pituitary, with an internal disulfide bond between its two cysteines.
PT-141 (bremelanotide) is a synthetic cyclic melanocortin-receptor agonist.
Blend — 10 mg PT-141 + 5 mg Oxytocin
Our rankings are never for sale, and we make no health or dosing claims. Research compounds are for laboratory use only.